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Abstract
Surgery and radiotherapy are currently accepted alternatives for the treatment of localized
prostate cancer. In the absence of relevant randomized trials no decision regarding the superiority
of any of the given approaches can be made. Up to now several cohort-based approaches indicate
similar outcomes for both treatments. Based on a new population based approach, Merglen and
co-workers recently concluded that surgery would offer the best chance of long-term control in
terms of 10-year survival for T1–T3 prostate cancer patients. Unfortunately the strength of this
trial is limited by several shortcomings. Most importantly, issues of radiation dosage have not been
taken into account. In addition, several relevant parameters including Gleason score and PSA are
not well balanced between the arms and the assignment to arbitrary risk groups does not reflect
the real biological behaviour. Thus, the data provided do not support the strong conclusion issued
by the authors. Based on the data available, surgery and radiotherapy still have to be considered as
equally effective.
Commentary
Despite an intense debate over the last decades, there is no
agreement today on the treatment of choice for localized
prostate cancer. This is mainly due to the absence of large
randomized trials comparing radical prostatectomy and
radiation-based approaches. Therefore, clinicians have to
rely on retrospective and population-based trials which,
due to their nature, comprise a considerable risk of misin-
terpretation and must be analyzed very carefully [1].
In this regard, a Swiss group performed a population
based analysis on treatment outcome after radiotherapy
or surgery for prostate cancer in the Geneva region [2],
which is, unfortunately, subject to an array of methodo-
logical pitfalls and misinterpretations.
This trial is a retrospective observational cohort study on
844 T1–3 prostate cancer patients documented in the
Geneva Cancer Registry with a treatment period from
1989 to 1998.
The authors state, that the 5-year overall- and cancer-spe-
cific survival rates were almost identical for radiotherapy
and prostatectomy but worse for the other treatment
options. After ten years, the authors noted, that prostate
cancer specific survival was inferior in radiotherapy-only
patients when compared to surgery-only patients. No
such difference was seen when surgery-only was com-
pared to radiotherapy plus hormonal ablation. Watchful
waiting and hormonal treatment only were found to have
inferior outcomes.
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These conclusions are based on the endpoint "mortality
from prostate cancer". Yet, the authors fail to provide a
definition for this endpoint, which itself is difficult to
assess. It has been shown, that the cause of death in
patients with prostate cancer is easily misattributed [3].
Since this aspect, concerning the most important end-
point of the study, is totally ignored by Merglen et al, mis-
interpretation of the data is due to happen.
Additionally, there are several further shortcomings that
limit the value of the current study, most of which con-
cern confounding variables:
First, the Gleason score is missing in 15% of the radiother-
apy patients and in only 3% of the surgical patients. Fur-
thermore, the grouping of patients was not based on the
Gleason score only, but on a mixture of Gleason score and
grading. The result is, that patients with a Gleason of 7 are
analyzed in the same group as patients with a Gleason of
10, despite the fact that these scores represent distinct risk
populations [4]. Another important predictor for the out-
come after treatment is the initial PSA level. Again, there
is a severe imbalance with 37% of the radiotherapy
patients having PSA levels higher than 20 ng/ml whereas
only 27% of the surgical patients had such PSA values.
Moreover, there was a difference of 8% in patients with a
PSA level above 30 ng/ml in favour of the surgical group.
Next, there is the issue of the lymph node status: There is
no hint, on how patients in the radiotherapy group have
been staged. Resected patients are prone to have had path-
ological staging, whereas radiotherapy patients probably
had computed tomography, which is known to be unreli-
able in this regard [5,6]. Thus, another bias is introduced.
The authors employed a Cox-regression model to adjust
for given imbalances. This model should be able to con-
trol for imbalanced confounding factors if the influence of
these factors is equally distributed in all subgroups.
Although the used Cox model is an adequate statistical
tool, it is doubtful whether statistical tools may be of any
use to make up for inadequate grouping of risk factors
(Gleason) or for a possible systematic clinical understag-
ing of certain patient collectives (N-status in radiotherapy
patients). At no point in their paper the authors indicated
possible weaknesses of this approach.
Last but not least, the authors completely neglected the
importance of adequate dosage for the outcome of radia-
tion-based treatment approaches [7-9]. In the last 15
years, advances in technical equipment allowed an escala-
tion of the prescribed dose to the level which is standard
nowadays. Since the trial by Merglen et al. was done in the
late eighties, it is likely that non-optimal radiation doses
were applied. Yet, the authors do not provide any data on
this aspect. Considering, that study patients with radio-
therapy and hormonal ablation show a comparable out-
come to surgical patients, the reason could be, that
hormonal therapy at least partially compensated for
underdosage [10].
In conclusion, the statement issued by Merglen and co-
workers that "surgery offers the best chance of long-term
prostate-cancer-specific survival in particular for younger
patients and patients with poorly differentiated tumours"
is not supported by the data presented in their paper. Most
of the obvious problems including the effects of radiation
dose, clinical vs. pathological staging as well as the attri-
bution of causes of death are not discussed by the authors.
The same is true for critical aspects on the discussed issue
in the papers that were already mentioned. Additionally,
there are data indicating an equivalence of radical prosta-
tectomy and radiotherapy, provided, that an adequate
radiation dose is prescribed [11-16], a fact, which is
neglected in the discussion.
Thus, despite the fact that observational studies are neces-
sary to evaluate the efficacy of surgery vs. radiotherapy in
prostate cancer, the paper by Merglen et al. does not add
valid information. In addition, we would be highly reluc-
tant to use these data for patient counselling as suggested
by the authors "Until clinical trials provide conclusive evi-
dence, physicians and patients should be informed of
these results and their limitations".
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